SG11201808541VA - Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use - Google Patents
Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and useInfo
- Publication number
- SG11201808541VA SG11201808541VA SG11201808541VA SG11201808541VA SG11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA SG 11201808541V A SG11201808541V A SG 11201808541VA
- Authority
- SG
- Singapore
- Prior art keywords
- rivig
- international
- immune
- proteins
- ste
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662315483P | 2016-03-30 | 2016-03-30 | |
| PCT/US2017/024650 WO2017172853A1 (en) | 2016-03-30 | 2017-03-29 | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201808541VA true SG11201808541VA (en) | 2018-10-30 |
Family
ID=59965144
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201808541VA SG11201808541VA (en) | 2016-03-30 | 2017-03-29 | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11304994B2 (ru) |
| EP (1) | EP3436484A4 (ru) |
| JP (1) | JP7075100B2 (ru) |
| KR (1) | KR102477536B1 (ru) |
| CN (1) | CN109312000A (ru) |
| AU (1) | AU2017245143B2 (ru) |
| BR (1) | BR112018070022A2 (ru) |
| CA (1) | CA3019530A1 (ru) |
| CL (1) | CL2018002769A1 (ru) |
| CO (1) | CO2018011457A2 (ru) |
| EA (1) | EA201891999A1 (ru) |
| IL (1) | IL261968A (ru) |
| MA (1) | MA44517A (ru) |
| MX (1) | MX2018011865A (ru) |
| SG (1) | SG11201808541VA (ru) |
| TW (1) | TWI801336B (ru) |
| WO (1) | WO2017172853A1 (ru) |
| ZA (1) | ZA201806767B (ru) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112004550A (zh) | 2017-12-14 | 2020-11-27 | 康诺贝林伦瑙有限公司 | 用于治疗视神经脊髓炎的重组IgG Fc多聚体 |
| US20210353752A1 (en) * | 2018-10-11 | 2021-11-18 | Momenta Pharmaceuticals, Inc. | Treatment with highly silylated igg compositions |
| AU2019360271A1 (en) * | 2018-10-18 | 2021-04-29 | Elanco Us Inc. | Fc variants with altered binding to neonatal Fc receptor (FcRn) for veterinary use |
| CN109793894A (zh) * | 2019-04-03 | 2019-05-24 | 长春西诺生物科技有限公司 | 犬免疫球蛋白在制备犬溶血性贫血药物中的应用 |
| JP2022547692A (ja) | 2019-09-13 | 2022-11-15 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 免疫複合体介在性腎臓障害の処置のための組み換えＩｇＧ Ｆｃ多量体 |
| CN112899301B (zh) * | 2021-01-29 | 2023-04-11 | 中国热带农业科学院热带生物技术研究所 | 一种木薯普通花叶病毒诱导的基因沉默系统及其应用 |
| CN115724988B (zh) * | 2021-08-26 | 2023-11-17 | 瑅安生物医药（杭州）有限公司 | 一种接近天然分子的多肽融合分子 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1106846C (zh) * | 1997-08-21 | 2003-04-30 | 宝酒造株式会社 | 抗癌症剂 |
| DE19963859A1 (de) | 1999-12-30 | 2001-07-12 | Apotech Res & Dev Ltd | Bi- oder Oligomer eines Di-, Tri-, Quattro- oder Pentamers von rekombinanten Fusionsproteinen |
| GB0015426D0 (en) | 2000-06-24 | 2000-08-16 | Univ Southampton | Method for generating soluble highly multimeric proteins |
| CA2437958C (en) | 2001-03-09 | 2018-10-30 | University Of Chicago | Polymeric immunoglobulin fusion proteins that target low-affinity fc.gamma.receptors |
| US7279329B2 (en) * | 2005-10-17 | 2007-10-09 | Industrial Technology Research Institute | Expression system for producing collagen |
| US20070264687A1 (en) | 2005-12-15 | 2007-11-15 | Min-Yuan Chou | Recombinant triplex scaffold-based polypeptides |
| GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
| EP2144930A1 (en) | 2007-04-18 | 2010-01-20 | ZymoGenetics, Inc. | Single chain fc, methods of making and methods of treatment |
| NZ581395A (en) | 2007-05-14 | 2012-08-31 | Biogen Idec Inc | Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto |
| EP2641913B1 (en) * | 2007-06-01 | 2018-04-18 | University of Maryland, Baltimore | Immunoglobulin constant region Fc receptor binding agents |
| WO2010065578A2 (en) | 2008-12-04 | 2010-06-10 | Leukosight Inc. | POLYPEPTIDES COMPRISING Fc FRAGMENTS OF IMMUNOGLOBULIN G (IgG) AND METHODS OF USING THE SAME |
| TWI588157B (zh) | 2010-07-28 | 2017-06-21 | 吉林尼克公司 | 產生依序多聚體化免疫球蛋白ｆｃ組合物之天然人類蛋白質片段之融合蛋白 |
| EP2561888A1 (en) | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
| TWI476001B (zh) | 2011-12-26 | 2015-03-11 | Ind Tech Res Inst | 三倍體Ｆｃ融合蛋白及其用途 |
| AU2013295647B2 (en) * | 2012-07-26 | 2018-02-08 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Multimeric fusion protein vaccine and immunotherapeutic |
| MX2015002269A (es) | 2012-08-20 | 2015-07-06 | Gliknik Inc | Moleculas con actividad de union al antigeno y al receptor fc gamma polivalente. |
| EP2908914B1 (en) | 2012-10-17 | 2018-04-18 | Liverpool School of Tropical Medicine | Immunomodulatory proteins |
| HUE060464T2 (hu) | 2013-03-13 | 2023-03-28 | Genzyme Corp | PDGF- és VEGF-kötõrészeket tartalmazó fúziós fehérjék és eljárások azok alkalmazására |
| US20150038682A1 (en) | 2013-08-02 | 2015-02-05 | Jn Biosciences Llc | Antibodies or fusion proteins multimerized via homomultimerizing peptide |
| BR112016023948A2 (pt) | 2014-04-16 | 2018-01-30 | Ucb Biopharma Sprl | proteínas fc multiméricas |
| CN108289928A (zh) | 2015-08-06 | 2018-07-17 | 哈佛大学校长及研究员协会 | 改进的微生物-结合分子和其用途 |
-
2017
- 2017-03-29 WO PCT/US2017/024650 patent/WO2017172853A1/en active Application Filing
- 2017-03-29 EP EP17776516.1A patent/EP3436484A4/en active Pending
- 2017-03-29 KR KR1020187030960A patent/KR102477536B1/ko active IP Right Grant
- 2017-03-29 CN CN201780033114.8A patent/CN109312000A/zh active Pending
- 2017-03-29 SG SG11201808541VA patent/SG11201808541VA/en unknown
- 2017-03-29 CA CA3019530A patent/CA3019530A1/en active Pending
- 2017-03-29 MA MA044517A patent/MA44517A/fr unknown
- 2017-03-29 US US16/089,042 patent/US11304994B2/en active Active
- 2017-03-29 EA EA201891999A patent/EA201891999A1/ru unknown
- 2017-03-29 MX MX2018011865A patent/MX2018011865A/es unknown
- 2017-03-29 BR BR112018070022A patent/BR112018070022A2/pt unknown
- 2017-03-29 AU AU2017245143A patent/AU2017245143B2/en active Active
- 2017-03-29 JP JP2019503393A patent/JP7075100B2/ja active Active
- 2017-03-30 TW TW106110897A patent/TWI801336B/zh active
-
2018
- 2018-09-26 IL IL261968A patent/IL261968A/en unknown
- 2018-09-28 CL CL2018002769A patent/CL2018002769A1/es unknown
- 2018-10-11 ZA ZA2018/06767A patent/ZA201806767B/en unknown
- 2018-10-26 CO CONC2018/0011457A patent/CO2018011457A2/es unknown
-
2022
- 2022-03-29 US US17/707,243 patent/US11801286B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017245143A1 (en) | 2018-10-18 |
| US11801286B2 (en) | 2023-10-31 |
| EP3436484A4 (en) | 2019-12-04 |
| CN109312000A (zh) | 2019-02-05 |
| BR112018070022A2 (pt) | 2019-02-05 |
| CA3019530A1 (en) | 2017-10-05 |
| WO2017172853A1 (en) | 2017-10-05 |
| JP7075100B2 (ja) | 2022-05-25 |
| MX2018011865A (es) | 2019-03-28 |
| TWI801336B (zh) | 2023-05-11 |
| EA201891999A1 (ru) | 2019-08-30 |
| TW201741335A (zh) | 2017-12-01 |
| JP2019513024A (ja) | 2019-05-23 |
| US20220233658A1 (en) | 2022-07-28 |
| MA44517A (fr) | 2019-02-06 |
| KR20180132731A (ko) | 2018-12-12 |
| CL2018002769A1 (es) | 2018-12-28 |
| US11304994B2 (en) | 2022-04-19 |
| EP3436484A1 (en) | 2019-02-06 |
| KR102477536B1 (ko) | 2022-12-13 |
| CO2018011457A2 (es) | 2019-02-08 |
| ZA201806767B (en) | 2023-04-26 |
| US20190111115A1 (en) | 2019-04-18 |
| IL261968A (en) | 2018-10-31 |
| AU2017245143B2 (en) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808541VA (en) | Recombinant intravenous immunoglobulin (rivig) compositions and methods for their production and use | |
| SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
| SG11201906297QA (en) | Nucleic acids encoding crispr-associated proteins and uses thereof | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201908540PA (en) | Stable antibody formulation | |
| SG11201809700YA (en) | Gdf15 fusion proteins and uses thereof | |
| SG11201900955VA (en) | T cell receptors and immune therapy using the same | |
| SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
| SG11201810697QA (en) | Chimeric antigen receptor and car-t cells that bind bcma | |
| SG11201807590SA (en) | Transfected t-cells and t-cell receptors for use in immunotherapy against cancers | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof | |
| SG11201906264YA (en) | Improved serum albumin binders | |
| SG11201803975SA (en) | Improved tnf binders | |
| SG11201408095XA (en) | Fibroblast growth factor 21 proteins | |
| SG11201906341XA (en) | Improved serum albumin binders | |
| SG11201900745VA (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
| SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
| SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| SG11201811737SA (en) | Novel fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease | |
| SG11201903693QA (en) | Polypeptide variants and uses thereof | |
| SG11201907646YA (en) | Proteins binding her2, nkg2d and cd16 |